A Phase I Clinical Study of Hemay808

NCT04100642 | Completed Phase 1

• 1 other identifier: YQ-M-18-08
• Study Type: interventional
• Target: 42
• Locations: 1 country
• Sites: 1

Brief Summary

This is a first-in-human study in health volunteers. The purpose is the local tolerability and systemic safety of Hemay808, which is an ointment made of a novel small molecule Hemay028. The safety and systemic pharmacokinetics (PK) of Hemay028 will be evaluated following topical application of Hemay808 to healthy volunteers.

Conditions

Safety Issues

Keywords

first in human; atopic dermatitis

Outcome Measures

Primary Outcomes (1)

• Number of adverse events and serious adverse events.

  Incidence of AEs

  Day 1 to Day 30

Secondary Outcomes (4)

• Cmax

  pre-dose, 0.5, 1, 2, 3, 5, 8, 12, 14, 24, 36, 48, 72 hours post-dose

• Tmax

  pre-dose, 0.5, 1, 2, 3, 5, 8, 12, 14, 24, 36, 48, 72 hours post-dose

• AUCt

  pre-dose, 0.5, 1, 2, 3, 5, 8, 12, 14, 24, 36, 48, 72 hours post-dose

• AUC∞

  pre-dose, 0.5, 1, 2, 3, 5, 8, 12, 14, 24, 36, 48, 72 hours post-dose

Study Arms (6)

1% Hemay808 apply to 25%BSA

ACTIVE COMPARATOR

8 subjects use 1% Hemay808

Drug: Hemay808

3% Hemay808 apply to 25%BSA

EXPERIMENTAL

8 subjects use 3% Hemay808

Drug: Hemay808

3% Hemay808 apply to 55%BSA

EXPERIMENTAL

6 subjects use 3% Hemay808

Drug: Hemay808

7% Hemay808 apply to 25%BSA

EXPERIMENTAL

8 subjects use 7% Hemay808

Drug: Hemay808

placebo apply to 25%BSA

PLACEBO COMPARATOR

6 subjects use placebo apply to 25%BSA

Drug: Placebo

placebo apply to 55%BSA

PLACEBO COMPARATOR

2 subjects use placebo apply to 55%BSA

Drug: Placebo

Interventions

Hemay808 DRUG

topical apply

1% Hemay808 apply to 25%BSA; 3% Hemay808 apply to 25%BSA; 3% Hemay808 apply to 55%BSA; 7% Hemay808 apply to 25%BSA

Placebo DRUG

topical apply

placebo apply to 25%BSA; placebo apply to 55%BSA

Eligibility Criteria

• Age: 18 Years - 45 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Pediatric subjects aged ≥ 18 to 45 years, inclusive.
• Male weight 50kg during screening; Female weight 45kg; Body mass index (BMI) between 19 and 24kg/m2 (including boundary value).
• No ulceration, injury, sunburn, redness, rash, pigmentation, uneven skin color, excessive freckles or abnormal fever were found in the skin of the target coating area during screening and before administration.
• Chinese health volunteers
• Women of child-bearing age and all male subjects must undertake to take effective contraceptive measures during the study period and within 6 months after discontinuation of the medication.
• All subjects will voluntarily participate in the study after knowing the content of the study and possible adverse drug reactions (ADR), and must sign the informed consent approved by the ethics committee before starting to accept any inspection specified in this study.
• Subjects will be able to communicate well with the investigator and promise to complete the study in accordance with the study regulations.

You may not qualify if:

• History of mental illness or a genetic history of mental illness, or a history of serious (5.0 NCI CTCAE 3) cardiovascular, liver, kidney, digestive tract, neurological or other diseases.
• Any dermatological condition other than atopic dermatitis that in the Investigator's opinion may interfere with the evaluation of the patient's atopic dermatitis.
• History of atopic dermatitis.
• History of severe (5.0 NCI CTCAE 3) skin disease.
• Current diagnosis or history allergic disease (such as allergic nose pharynx, allergic asthma), has a history of drug allergy, always have a skin allergy (including but not limited to allergic to the patch, for metal, cosmetics and household items with contact dermatitis), known to gao min physique, or known or the judge may, the active ingredient to the study drug has allergies or accessories.
• Regular smoking (\>5 / day) or drinking (\>28 units/day); Unit: 285mL beer or 25mL spirits or 100mL wine); Or drink too much tea every day (\>15g tea/day); Generally, each time tea is brewed (3\~5g of tea), coffee or drinks containing caffeine (\>500mg/ day) (one cup of coffee contains about 85mg of caffeine).
• Subjects were not negative by virological examination (hepatitis b surface antigen, hepatitis c antibody, human immunodeficiency virus) and gelagglutination test of treponema pallidum.
• Common drugs (MDMA, MOR, MAMP, KETA) did not meet the requirements.
• Have major surgery within 2 months prior to screening, or have any surgery within 4 weeks prior to screening.
• Had treated cancer within 5 years prior to screening (except for squamous cell, basal cell, or in situ skin cancers that were cured only by cryopreservation or surgical excision).
• History of use (including topical use) for any reason within 2 weeks prior to administration. Except the investigator determines that the drug used has a half-life of \>5 years after the start of this study, the corresponding subjects can also be enrolled.
• Have a history of drug abuse or drug abuse, or regularly (\>3 times/week within 3 months before screening) use Chinese herbs, tranquilizers, sleeping pills, tranquilizers and other addictive drugs.
• Participated in any clinical trial within 3 months prior to screening.
• Non-physiologic blood loss 400ml (including trauma, blood collection and blood donation) within 3 months prior to screening, or blood donation during the study period or within 1 month after the study.
• The female subjects were in lactation or pregnancy at the time of screening (meaning the serum human chorionic gonadotropin test results of female subjects of child-bearing age were higher than the reference value).

Sponsors & Collaborators

• Tianjin Hemay Pharmaceutical Co., Ltd: lead

Study Sites (1)

Dermotology hospital, Chinese academy of medical science

Nanjing, Jiangsu, 210042, China

Location

MeSH Terms

Conditions

Dermatitis, Atopic

Condition Hierarchy (Ancestors)

Skin Diseases, Genetic; Genetic Diseases, Inborn; Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Dermatitis; Skin Diseases; Skin and Connective Tissue Diseases; Skin Diseases, Eczematous; Hypersensitivity, Immediate; Hypersensitivity; Immune System Diseases

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: TRIPLE
• Who Masked: PARTICIPANT, INVESTIGATOR, OUTCOMES ASSESSOR
• Purpose: TREATMENT
• Intervention Model: SEQUENTIAL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: May 20, 2019
• First Posted: September 24, 2019
• Study Start: April 8, 2019
• Primary Completion: October 23, 2019
• Study Completion: December 22, 2019
• Last Updated: April 27, 2020

Record last verified: 2019-09

Locations

CN (1)